NCT02512575View on ClinicalTrials.gov

A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 18, 2015

Primary Completion Date

September 26, 2016

Study Completion Date

September 26, 2016

Conditions
SafetyTolerabilityPharmacokineticsPharmacodynamicsHealthy SubjectsRheumatoid Arthritis
Interventions
DRUG

AZD9567 Monohydrat

AZD9567 oral suspension 0.5 to 10 mg/ml

DRUG

Placebo oral suspension/ Placebo capsule

Matching placebo

DRUG

Prednisolone

Prednisolone 60mg oral capsules (12 capsules of 5 mg each).

Trial Locations (1)

14050

Research Site, Berlin

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY